LEADER 02469nam  2200685z- 450 
001 9910557665403321
005 20231214132837.0
035   $a(CKB)5400000000044852
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/76275
035   $a(EXLCZ)995400000000044852
100   $a20202201d2021      |y             0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aThe Immunology and Biology of Brain Tumors
210   $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021
215   $a1 electronic resource (88 p.)
311   $a3-0365-0102-9 
311   $a3-0365-0103-7 
330   $aImmunotherapy has become a viable treatment modality for a variety of cancers (and referred to as Science Magazine?s ?Breakthrough of the Year? in 2013, as well as ASCO?s ?Advance of the Year? in both 2016 and 2017). This Special Issue is focused on the relevance of immunobiology in brain tumors, touching on elements of immune suppression, immune stimulation, and the immune microenvironment, with culminations in translational immunotherapy.
606   $aMedicine$2bicssc
610   $avaccine therapy
610   $aoncoantigen
610   $atumor associate antigen
610   $atumor angiogenesis
610   $ahigh-grade glioma
610   $apituitary neuroendocrine tumors
610   $aVEGF
610   $aTreg
610   $aTAM
610   $aPD-1
610   $aPD-L1
610   $atumor microenvironment (TME)
610   $aglioblastoma multiforme (GBM)
610   $aGBM-associated macrophages (GAMs)
610   $aexosomes
610   $aoncomiR-21
610   $aSTAT3 inhibitor
610   $aglioma
610   $adiffusion tensor imaging
610   $ageneralized q-ball imaging
610   $atreatment-related effects
610   $amultiple resections
610   $aadrenal insufficiency
610   $aAddison?s disease
610   $abevacizumab
610   $acerebral radiation necrosis
610   $acraniopharyngioma
610   $ainflammation
610   $acheckpoint inhibitors
610   $aInterleukin-6
615  7$aMedicine
700   $aGraner$b Michael$4edt$01327016
702   $aGraner$b Michael$4oth
906   $aBOOK
912   $a9910557665403321
996   $aThe Immunology and Biology of Brain Tumors$93037797
997   $aUNINA